Assessment of pazopanib-related hypertension, cardiac dysfunction and identification of clinical risk factors for their development


Background Antineoplastic therapy with the tyrosine kinase inhibitor pazopanib in patients with advanced/metastatic renal cell carcinoma (mRCC) has been associated with hypertension (HTN), cardiomyopathy, and cardiac dysrhythmias. We therefore assessed the cardiovascular (CV) risk with pazopanib in a clinical setting. Methods Medical records of 35… (More)
DOI: 10.1186/s40959-017-0024-8


12 Figures and Tables